Palifermin
Top View
- ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-Up† D
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Hazardous Drug Acknowledgement Statement
- Medical Benefit Injectable Drugs | Kaiser Permanente Washington
- 2019 Table of Drugs
- NIOSH Hazardous Drugs Table 1 Antineoplastic Drugs
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Effectiveness of an Algorithm-Based Approach to Filgrastim-Based
- Drug and Nutrition in Cancer Patient
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
- Clinical Practice Guidelines for the Prevention and Treatment of EGFR Inhibitor-Associated Dermatologic Toxicities
- Pharmacist Involvement in the Management of Adverse Effects
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Development of the Rat Model of Lapatinib-Induced Diarrhoea
- National Direct Drug List
- SUMMARY of DRUG LIMITATIONS Medications Listed in This Document May Or May Not Require a Prior Authorization
- New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome Leah J
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red